Syndax Pharmaceuticals reported a quarterly loss of $0.48 per share, beating the Zacks Consensus Estimate for a $0.59 loss by $0.11 per share. The company also improved meaningfully from a loss of $0.98 per share a year ago, indicating better operating performance despite remaining unprofitable.
Syndax Pharmaceuticals reported a quarterly loss of $0.48 per share, beating the Zacks Consensus Estimate for a $0.59 loss by $0.11 per share. The company also improved meaningfully from a loss of $0.98 per share a year ago, indicating better operating performance despite remaining unprofitable.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
